Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Highlights

The global methicillin-resistant Staphylococcus aureus (MRSA) drugs market is expected to cross a value of USD 5.9 billion by the end of 2032. The market was valued at USD 4.1 billion in 2023 and is expected to expand at a CAGR of 4.8% between 2024-2032.

• Over the mid-term, the increasing evolution of drug-resistant strains of MRSA is the primary factor anticipated to drive the global methicillin-resistant Staphylococcus aureus (MRSA) drugs market.
• The rising concern for diminishing antibiotic resistance is a major factor to challenge the market growth.
• The North America methicillin-resistant Staphylococcus aureus (MRSA) drugs market is projected to dominate the global market.

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Outlook

The medications that are specifically designed to treat infections caused by the bacteria Staphylococcus aureus, and that these bacteria have developed resistance to methicillin and other beta-lactam antibiotics, is known as methicillin-resistant Staphylococcus aureus (MRSA) drugs. MRSA infections usually range from mild skin to severe infections, and can also be life threating, such as pneumonia, surgical site infections, and bloodstream infections among others.

As per our researchers at KD Market Insights, the increasing evolution of drug-resistant strains of MRSA is one of the primary factors expected to boost the growth of the methicillin-resistant Staphylococcus aureus (MRSA) drugs market. Our experts have found that the pooled prevalence rates of MRSA worldwide was near to 15% in 2022, while the World Health Organization stated that the proportion of bloodstream infection due to MRSA touched 35% in 2020 up from 21% in 2016. Pfizer, Inc., Allergan Plc., and Johnsons & Johnson are some of the significant parties in the global market for methicillin-resistant Staphylococcus aureus (MRSA) drugs.

                           Get More Insights on This Report - Request Free Sample PDF

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Drivers – Analyst’s Observation

According to the analysts at KD Market Insights, some key growth drivers for the global methicillin-resistant Staphylococcus aureus (MRSA) drugs market are:

• Rise in Incidence of MRSA Infections: Globally, the prevalence of methicillin-resistant Staphylococcus aureus (MRSA) infections are increasing. This, as a result, has raised the need for medications that can help treat the disease. Alternatively, the healthcare facilities around the globe are implementing stringent infection control measures to prevent the spread of MRSA infections, which is also raising the demand for effective treatment of the disease. Such a factor is therefore expected to drive the growth of MRSA drugs market.
• Rapid Advancements in Drug Development: The pharmaceutical drug manufacturers around the globe are increasingly working on discovering new antibiotics and therapeutics for treating MRSA infections, supported by the rising healthcare expenditure, particularly in developed countries. With the growing healthcare infrastructure worldwide, and increasing access to medical care, advancements in drug development, such as novel mechanisms of action, improved efficacy, and reduced toxicity, are bound to happen, thereby contributing massively to the growth of the market.

Which Probable Factors Could Hamper the Growing Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Trend?

As per our KD Market Insights analysis, some of the challenges expected to limit the global market growth of methicillin-resistant Staphylococcus aureus (MRSA) drugs are:

• Rising Concern for Diminishing Antibiotic Resistance: The development of resistance to existing MRSA drugs poses a significant challenge in the treatment of MRSA infections. As MRSA strains become resistant to multiple antibiotics, including those considered last-resort treatments, the effectiveness of available drugs diminishes, limiting treatment options and restraining market growth.
• Growing Availability of Generic Versions of MRSA Drugs: The availability of generic versions of MRSA drugs, particularly older antibiotics like vancomycin and linezolid, leads to pricing pressures and reduced profit margins for drug manufacturers, which is expected to hinder the market growth.

How is the Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Segmented?

Our experts at KD Market Insights have segmented the global methicillin-resistant Staphylococcus aureus (MRSA) drugs market as:

What are the Probable Factors Influencing the North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Forecast?

The North America methicillin-resistant Staphylococcus aureus (MRSA) drugs market is majorly driven by the fact that the region has experienced a significant burden of MRSA infections, particularly in healthcare settings, which is driving the demand for effective MRSA drugs. According to the statistics by the United States Centers for Disease Control and Prevention (CDC), 9830 MRSA infections were reported in the year 2022 in the U.S. The current threat report provided by the U.S. CDC also stated that there were 323,700 estimated cases and 10,600 estimated deaths as a result of the disease. Alternatively, the presence of an advanced healthcare infrastructure in the region, particularly in the United States, along with the improving access to medical services, that facilitates the diagnosis and treatment of MRSA infections, is also expected to contribute to the market growth.

As per our analysts at KD Market Insights, the following five players lead the North America methicillin-resistant Staphylococcus aureus (MRSA) drugs market growth:

• Pfizer Inc.
• Merck & Co., Inc.
• Allergan plc (now part of AbbVie)
• GlaxoSmithKline plc
• Cubist Pharmaceuticals (acquired by Merck & Co., Inc.)

Which Key Players Top the Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Share?

As per our analysts at KD Market Insights, the competitive landscape of global methicillin-resistant Staphylococcus aureus (MRSA) drugs market facilitates our readers in identifying their closest competitors. The manufacturers who are associated with methicillin-resistant Staphylococcus aureus (MRSA) drugs market are raising their focus on expanding their presence, as well as their market share. The market has also been witnessing an upward movement in the number of collaborations between research institutions and key players, aimed at introducing advanced technologies and innovation of new products. Here is a list of the key players who top the global methicillin-resistant Staphylococcus aureus (MRSA) drugs market share:

• Pfizer, Inc.
• Allergan Plc.
• Johnsons & Johnson
• Colgate-Palmolive Company
• The Procter & Gamble
• Merck & Co., Inc.
• Baxter Healthcare Corporation
• Fresenius Kabi LLC
• Sandoz Inc.
• Teva Pharmaceutical Industries ltd.
• Mylan N. V.
• Dr.Reddy's Laboratories Inc.
• Cumberland Pharmaceuticals Inc.
• Durata Therapeutics Inc.
• Melinta Therapeutics, Inc.
• Debiopharm International S.A.
• Cardinal Health
• Amazon Inc.
• Herbal Intervention, LLC
• 3M ESPE Dental Products
• Patterson Dental Supply Inc.
• The Kroger Company
• Crown Laboratories, Inc.
• Atlantic Biologicals Corp.
• Bio-Germ Protection LLC
• Apollo Health
• Beauty Care

What are the Recent Developments Observed in the Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market?

Over the years, the experts at KD Market Insights have been observing the recent developments associated with global methicillin-resistant Staphylococcus aureus (MRSA) drugs market trends. Our expert’s market forecast analysis has recorded the market players adopting plentiful of key strategies including new product launches, mergers & acquisitions, and collaborations.

For instance, Melinta Therapeutics stated that it has commercially launched its lipoglycopeptide antibiotic, known as KIMYRSA. This antibiotic works as a complete course of therapy for acute bacterial skin and skin structure infections.

Further, Wockhardt shared that it has received regulatory approval for its two novel antibiotics, namely, EMROK (IV), and EMROK O (Oral). These two antibiotics are used for treating acute bacterial skin and skin structure infections.